1 – 10 of 72
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2020
-
Mark
Direct comparison of two extended half-life PEGylated recombinant FVIII products : a randomized, crossover pharmacokinetic study in patients with severe hemophilia A
(
- Contribution to journal › Article
-
Mark
Modeling to Predict Factor VIII Levels Associated with Zero Bleeds in Patients with Severe Hemophilia A Initiated on Tertiary Prophylaxis
(
- Contribution to journal › Article
- 2019
-
Mark
Genome-Wide Association Transethnic Meta-Analyses Identifies Novel Associations Regulating Coagulation Factor VIII and von Willebrand Factor Plasma Levels
(
- Contribution to journal › Article
-
Mark
Recombinant factor VIII products and inhibitor development in previously untreated patients with severe haemophilia A : Combined analysis of three studies
(
- Contribution to journal › Article
- 2018
-
Mark
Pharmacokinetic modelling and validation of the half-life extension needed to reduce the burden of infusions compared with standard factor VIII
(
- Contribution to journal › Article
-
Mark
Immune tolerance induction : What have we learned over time?
(
- Contribution to journal › Scientific review
-
Mark
How I manage patients with inherited haemophilia A and B and factor inhibitors
(
- Contribution to journal › Scientific review
- 2017
-
Mark
European retrospective study of real-life haemophilia treatment
(
- Contribution to journal › Article
-
Mark
Intensity of factor VIII treatment and the development of inhibitors in non-severe hemophilia A patients : Results of the INSIGHT case-control study
(
- Contribution to journal › Article
-
Mark
Primary prophylaxis in haemophilia care : Guideline update 2016
(
- Contribution to journal › Article